176 related articles for article (PubMed ID: 31903638)
1. Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis.
Goklemez S; Im AP; Cao L; Pirsl F; Steinberg SM; Curtis LM; Mitchell SA; Cowen EW; Baruffaldi J; Rose J; Mays J; Ostojic A; Holtzman NG; Hakim FT; Pavletic SZ
Am J Hematol; 2020 Apr; 95(4):387-394. PubMed ID: 31903638
[TBL] [Abstract][Full Text] [Related]
2. Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation.
Lertkovit O; Anurathapan U; Hongeng S; Thokanit NS; Pakakasama S
Int J Hematol; 2021 Apr; 113(4):556-565. PubMed ID: 33385291
[TBL] [Abstract][Full Text] [Related]
3. Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versus-host disease.
Ljubas Kelecic D; Lelas A; Karas I; Desnica L; Vukic T; Sabol I; Vranesic Bender D; Serventi Seiwerth R; Peric Z; Durakovic N; Vitali Cepo D; Vrhovac R; Nemet D; Pavletic S; Pulanic D; Krznaric Z
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2967-2978. PubMed ID: 32507973
[TBL] [Abstract][Full Text] [Related]
4. Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.
Grkovic L; Baird K; Steinberg SM; Williams KM; Pulanic D; Cowen EW; Mitchell SA; Hakim FT; Martires KJ; Avila DN; Taylor TN; Salit RB; Rowley SD; Zhang D; Fowler DH; Bishop MR; Gress RE; Pavletic SZ
Leukemia; 2012 Apr; 26(4):633-43. PubMed ID: 22005783
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.
Kuzmina Z; Gounden V; Curtis L; Avila D; Rnp TT; Baruffaldi J; Cowen EW; Naik HB; Hasni SA; Mays JW; Mitchell S; Baird K; Steinberg SM; Pavletic SZ
Am J Hematol; 2015 Feb; 90(2):114-9. PubMed ID: 25363867
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Gazourian L; Rogers AJ; Ibanga R; Weinhouse GL; Pinto-Plata V; Ritz J; Soiffer RJ; Antin JH; Washko GR; Baron RM; Ho VT
Am J Hematol; 2014 Apr; 89(4):404-9. PubMed ID: 24375545
[TBL] [Abstract][Full Text] [Related]
7. Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients.
Curtis LM; Pirsl F; Steinberg SM; Mitchell SA; Baird K; Cowen EW; Mays J; Buxbaum NP; Pichard DC; Im A; Avila D; Taylor T; Fowler DH; Gress RE; Pavletic SZ
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1980-1988. PubMed ID: 28797782
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
9. Oral chronic graft-vs.-host disease characterization using the NIH scale.
Fassil H; Bassim CW; Mays J; Edwards D; Baird K; Steinberg SM; Williams KM; Cowen EW; Mitchell SA; Hakim FT; Taylor T; Avila D; Zhang D; Grkovic L; Datiles M; Gress RE; Pavletic SZ
J Dent Res; 2012 Jul; 91(7 Suppl):45S-51S. PubMed ID: 22699667
[TBL] [Abstract][Full Text] [Related]
10. Genital chronic graft-versus-host disease in females: a cross-sectional study.
Smith Knutsson E; Björk Y; Broman AK; Helström L; Levin Jakobsen AM; Nilsson O; Sundfeldt K; Brune M
Biol Blood Marrow Transplant; 2014 Jun; 20(6):806-11. PubMed ID: 24594123
[TBL] [Abstract][Full Text] [Related]
11. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
12. Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation.
Doehn JM; Winkler A; Kuzmina Z; Hladik A; Greinix H; Knapp S; Robak O
Exp Hematol; 2016 Oct; 44(10):917-23. PubMed ID: 27403536
[TBL] [Abstract][Full Text] [Related]
13. Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation.
Hao B; Gao S; Sang YW; Wang L; Meng XQ; You JY
J Zhejiang Univ Sci B; 2019 Oct.; 20(10):849-860. PubMed ID: 31489804
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
15. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.
Bohmann EM; Fehn U; Holler B; Weber D; Holler E; Herr W; Hoffmann P; Edinger M; Wolff D
Ann Hematol; 2017 Feb; 96(2):299-310. PubMed ID: 27942862
[TBL] [Abstract][Full Text] [Related]
16. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
[TBL] [Abstract][Full Text] [Related]
17. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.
Jacobson CA; Sun L; Kim HT; McDonough SM; Reynolds CG; Schowalter M; Koreth J; Cutler CS; Ho VT; Alyea EP; Armand P; Blazar BR; Soiffer RJ; Antin JH; Ritz J; Sarantopoulos S
Biol Blood Marrow Transplant; 2014 May; 20(5):668-75. PubMed ID: 24462743
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia.
Lv M; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X; Mo X
Front Med; 2019 Dec; 13(6):667-679. PubMed ID: 31512033
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease.
Baumrin E; Baker LX; Byrne M; Martin PJ; Flowers ME; Onstad L; El Jurdi N; Chen H; Beeghly-Fadiel A; Lee SJ; Tkaczyk ER
JAMA Dermatol; 2023 Apr; 159(4):393-402. PubMed ID: 36884224
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of the cytokine panel in the diagnosis of ocular chronic graft-versus-host disease].
Cheng XJ; Ji R; Huan RH; Huang SQ; Fan W; Zhao YC; Yuan RD; Wang XQ; Zhang X
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):242-248. PubMed ID: 38716595
[No Abstract] [Full Text] [Related]
[Next] [New Search]
